Monopar Therapeutics (MNPR): Total Liabilities
$2.89M
As of 2025-12-31
$4.12M
As of 2026-06-30
-2.7%
3-year compound annual growth
+19.7%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.89M | -45.0% | 2026-03-27, Balance as of period end |
| 2024-12-31 | $5.25M | +199.0% | 2026-03-27, Balance as of period end |
| 2023-12-31 | $1.76M | -44.0% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $3.14M | +98.5% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $1.58M | +34.3% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $1.18M | +62.5% | 2022-03-24, Balance as of period end |
| 2019-12-31 | $724.2K | +81.2% | 2021-03-25, Balance as of period end |
| 2018-12-31 | $399.6K | +28.1% | 2020-03-27, Balance as of period end |
| 2017-12-31 | $311.9K | +383.4% | 2019-02-26, Balance as of period end |
| 2016-12-31 | $64.5K | n/a | 2018-03-26, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | 2025-12-31 | $2.89M | -45.0% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $71.53B | -6.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $10.78M | -5.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $121.39B | -2.8% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $117.67B | +8.3% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $99.59M | +24.7% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $7.00M | +0.4% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $3.14M | -44.7% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $241.54M | -9.5% |
Compare MNPR, BMY, TXMD, PFE side by side · Screen every company in Pharmaceutical Preparations ↗